CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
